182 related articles for article (PubMed ID: 35275208)
1. Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.
Zhang W; Gong C; Peng X; Bi X; Sun Y; Zhou J; Wu F; Zeng H; Wang Y; Zhou H; Zhao H; Cai J; Zhou A
Clin Cancer Res; 2022 Aug; 28(16):3499-3508. PubMed ID: 35275208
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.
Liu D; Mu H; Liu C; Zhang W; Cui Y; Wu Q; Zhu X; Fang F; Zhang W; Xing W; Li Q; Song T; Lu W; Li H
Neoplasma; 2023 Dec; 70(6):811-818. PubMed ID: 38247334
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
[TBL] [Abstract][Full Text] [Related]
6. A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma.
Zeng X; Jia Y; Chen H; Luo Q; Zhao H; Liang G; Chen W; Li Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9213-9219. PubMed ID: 37188985
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
8. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
[TBL] [Abstract][Full Text] [Related]
9. A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients.
Sun C; Wang Q; Hou L; Zhang R; Chen Y; Niu L
Front Immunol; 2023; 14():1229560. PubMed ID: 37575236
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
Front Immunol; 2022; 13():929141. PubMed ID: 35990634
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
16. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
Xu Z; Ye ZM; Tang YK; Deng DF; Zhou Q; Fang M; Zhang YY; Li XP
Cancer Med; 2023 Jul; 12(14):14871-14880. PubMed ID: 37434398
[TBL] [Abstract][Full Text] [Related]
18. Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary caner-specialized hospital in China.
Chen Z; Wang Y; Yang J; Zhou H; Li G
J Clin Pharm Ther; 2022 Dec; 47(12):2274-2278. PubMed ID: 36418209
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Front Pharmacol; 2022; 13():778505. PubMed ID: 35222020
[No Abstract] [Full Text] [Related]
20. Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review.
Liang X; Liu Q; Yao W; Zhu S
Front Oncol; 2022; 12():941454. PubMed ID: 36505782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
